Fluoxetine inhibits monocrotaline-induced pulmonary arterial remodeling involved in inhibition of RhoA-Rho kinase and Akt signalling pathways in rats

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 11, 2012, Pages 1506-1515

  Wang, Han Ming ^a   Wang, Yun ^a   Liu, Ming ^a,b   Bai, Yang ^a   Zhang, Xin Hua ^a   Sun, Ying Xian ^a   Wang, Huai Liang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CHINA CRIMINAL POLICE UNIVERSITY   (China)

Author keywords

Akt; Fluoxetine; Monocrotaline; Pulmonary arterial remodeling; Rho kinase; Rhoa; Serotonin transporter

Indexed keywords

FLUOXETINE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCROTALINE; PROTEIN KINASE B; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; HEMODYNAMICS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SIGNAL TRANSDUCTION;

AIRWAY REMODELING; ANIMALS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FLUOXETINE; HYPERTENSION, PULMONARY; ISOENZYMES; LUNG; MALE; MAP KINASE SIGNALING SYSTEM; MONOCROTALINE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; PULMONARY ARTERY; RANDOM ALLOCATION; RATS; RATS, WISTAR; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SEROTONIN UPTAKE INHIBITORS;

EID: 84870201800     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y2012-108     Document Type: Article

References (29)

1. Abe, K., Shimokawa, H., Morikawa, K., Uwatoku, T., Oi, K., Matsumoto, Y., et al. 2004. Long-term treatment with a Rhokinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. 94(3): -. doi:10.1161/01.RES.0000111804.34509.94. PMID:14670839.
2. Bressollette, E., Dupuis, J., Bonan, R., Doucet, S., Cernacek, P., and Tardif, J.C. 2001. Intravascular ultrasound assessment of pulmonary vascular disease in patients with pulmonary hypertension. Chest, 120(3): 809-815. doi:10.1378/chest.120.3.809. PMID: 11555514.
3. Chung, H.H., Dai, Z.K., Wu, B.N., Yeh, J.L., Chai, C.Y., Chu, K.S., et al. 2010. KMUP-1 inhibits pulmonary artery proliferation by targeting serotonin receptors/transporter and NO synthase, inactivating RhoA and suppressing AKT/ERK phosphorylation. Vascul. Pharmacol. 53(5-6): 239-249. doi:10.1016/j.vph.2010.09. 003. PMID:20870034.
4. Desbuards, N., Antier, D., Rochefort, G.Y., Apfeldorfer, C.S., Schenck, E., Hanton, G., and Hyvelin, J.-M. 2009. Dexfenfluramine discontinuous treatment does not worsen hypoxia-induced pulmonary vascular remodeling but activates RhoA-ROCK pathway: consequences on pulmonary hypertension. Eur. J. Pharmacol. 602(2-3): 355-363. doi:10.1016/j.ejphar.2008.11.025. PMID: 19049806.
5. Dhaliwal, J.S., Badejo, A.M., Jr, Casey, D.B., Murthy, S.N., and Kadowitz, P.J. 2009. Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl- 1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor. J. Pharmacol. Exp. Ther. 330(1): 334-341. doi:10.1124/jpet.109.151449. PMID: 19369577.
6. Eddahibi, S., Fabre, V., Boni, C., Martres, M.P., Raffestin, B., Hamon, M., and Adnot, S. 1999. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ. Res. 84(3): 329-336. doi:10.1161/01.RES.84.3.329. PMID:10024307.
7. Fukumoto, Y., Matoba, T., Ito, A., Tanaka, H., Kishi, T., Hayashidani, S., et al. 2005. Acute vasodilator effects of a Rhokinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart, 91(3): 391-392. doi:10.1136/hrt.2003. 029470. PMID:15710736.
8. Gary-Bobo, G., Houssaini, A., Amsellem, V., Rideau, D., Pacaud, P., Perrin, A., et al. 2010. Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats. Circulation, 122(19): 1937-1947. doi:10.1161/CIRCULATIONAHA.110.973750. PMID:20974998.
9. Girgis, R.E., Mozammel, S., Champion, H.C., Li, D., Peng, X., Shimoda, L., et al. 2007. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am. J. Physiol. Lung Cell. Mol. Physiol. 292(5): L1105-L1110. doi:10.1152/ajplung. 00411.2006. PMID:17277047.
10. Guignabert, C., Raffestin, B., Benferhat, R., Raoul, W., Zadigue, P., Rideau, D., et al. 2005. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation, 111(21): 2812-2819. doi:10.1161/ CIRCULATIONAHA.104.524926. PMID:15927991.
11. Guilluy, C., Sauzeau, V., Rolli-Derkinderen, M., Guerin, P., Sagan, C., Pacaud, P., and Loirand, G. 2005. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br. J. Pharmacol. 146(7): 1010-1018. doi:10.1038/sj.bjp.0706408. PMID:16205723.
12. Guilluy, C., Rolli-Derkinderen, M., Tharaux, P.L., Melino, G., Pacaud, P., and Loirand, G. 2007. Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J. Biol. Chem. 282(5): 2918-2928. doi:10.1074/jbc. M604195200. PMID:17142836.
13. Guilluy, C., Eddahibi, S., Agard, C., Guignabert, C., Izikki, M., Tu, L., et al. 2009. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am. J. Respir. Crit. Care Med. 179(12): 1151-1158. doi:10.1164/rccm.200805-691OC. PMID:19299501.
14. Henke, A., Huber, S., Stelzner, A., and Whitton, J.L. 1995. The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J. Virol. 69(11): 6720-6728. PMID:7474082.
15. Homma, N., Nagaoka, T., Karoor, V., Imamura, M., Taraseviciene-Stewart, L., Walker, L.A., et al. 2008. Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone. Am. J. Physiol. Lung Cell. Mol. Physiol. 295(1): L71-L78. doi:10.1152/ajplung.90251.2008. PMID:18469113.
16. Jaffe, A.B., and Hall, A. 2005. Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol. 21(1): 247-269. doi:10.1146/ annurev.cellbio.21.020604.150721. PMID:16212495.
17. Li, X.Q., Hong, Y., Wang, Y., Zhang, X.H., and Wang, H.L. 2006. Sertraline protects against monocrotaline-induced pulmonary hypertension in rats. Clin. Exp. Pharmacol. Physiol. 33(11): 1047-1051. doi:10.1111/j.1440-1681.2006.04485.x. PMID: 17042913.
18. Li, F., Xia, W., Li, A., Zhao, C., and Sun, R. 2007. Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats. Pharmacol. Res. 55(1): 64-71. doi:10.1016/j.phrs.2006.10.009. PMID:17127075.
19. Li, X.Q., Wang, H.M., Yang, C.G., Zhang, X.H., Han, D.D., and Wang, H.L. 2011. Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotalinetreated rats. Acta Pharmacol. Sin. 32(2): 217-222. doi:10.1038/ aps.2010.187. PMID:21217769.
20. Liu, Y., and Fanburg, B.L. 2006. Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1. Am. J. Respir. Cell Mol. Biol. 34(2): 182-191.doi:10.1165/rcmb.2005-0163OC. PMID:16195541.
21. Liu, Y., Suzuki, Y.J., Day, R.M., and Fanburg, B.L. 2004. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ. Res. 95(6): 579-586. doi:10.1161/01.RES.0000141428.53262.a4. PMID: 15297378.
22. Mair, K.M., MacLean, M.R., Morecroft, I., Dempsie, Y., and Palmer, T.M. 2008. Novel interactions between the 5-HT transporter, 5- HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts. Br. J. Pharmacol. 155(4): 606-616. doi:10.1038/bjp. 2008.310. PMID:18695640.
23. Matsusaka, S., and Wakabayashi, I. 2005. 5-Hydroxytryptamine as a potent migration enhancer of human aortic endothelial cells. FEBS Lett. 579(30): 6721-6725. doi:10.1016/j.febslet.2005.10.068. PMID:16310780.
24. McNamara, P.J., Murthy, P., Kantores, C., Teixeira, L., Engelberts, D., van Vliet, T., et al. 2008. Acute vasodilator effects of Rhokinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. Am. J. Physiol. Lung Cell. Mol. Physiol. 294(2): L205-L213. doi:10.1152/ajplung.00234.2007. PMID:18032699.
25. Nagaoka, T., Fagan, K.A., Gebb, S.A., Morris, K.G., Suzuki, T., Shimokawa, H., et al. 2005. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am. J. Respir. Crit. Care Med. 171(5): 494-499. doi:10.1164/ rccm.200405-637OC. PMID:15563635.
26. Oka, M., Fagan, K.A., Jones, P.L., and McMurtry, I.F. 2008. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br. J. Pharmacol. 155(4): 444-454. doi:10.1038/bjp. 2008.239. PMID:18536743.
27. Song, D., Wang, H.L., Wang, S., and Zhang, X.H. 2005. 5- Hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells are extracellular signal-regulated kinase pathway dependent. Acta Pharmacol. Sin. 26(5): 563-567. doi:10. 1111/j.1745-7254.2005.00071.x. PMID:15842774.
28. Walther, D.J., Peter, J.U., Winter, S., Holtje, M., Paulmann, N., Grohmann, M., et al. 2003. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell, 115(7): 851-862. doi:10.1016/S0092-8674(03) 01014-6. PMID:14697203.
29. Wang, Y., Zhang, X.H., and Wang, H.L. 2011. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline- induced endothelial apoptosis in rats. Can. J. Physiol. Pharmacol. 89(5): 345-354. doi:10.1139/y11-024. PMID: 21619414.